The higher incidences of neutropenia, thrombocytopenia and infection in the ASA404-CP group compared with the CP group were not expected on the basis of the safety profile for ASA404 monotherapy (Jameson et al, 2003; Rustin et al, 2003a; McKeage et al, 2006). This evidence concerns the gene CP and neutropenia.